Guidelines of the French Society of Otorhinolaryngology (SFORL) (short version). Specific treatment of epistaxis in Rendu-Osler-Weber disease

Malard, O.; Crampette, L.; Achache, M.; Lamrani, Moulay Youssef Alaoui; Ardillon, L.; Babin, E.; Sollier, Claire Bal dit; Béquignon, E.; Borsik, M.; Castillo, L.; Coste, A.; Debry, Christian; Dessi, P.; Drouet, Ludovic; Dufour, Xavier; Dupuis‐Girod, Sophie; Faure, Frédéric; Gallet, P.; Guldman, R.; Houdart, E; Jankowski, R.; Jégoux, Franck; Leble, S.; Michel, J.; Mortuaire, G.; Mouchon, E.; Page, C.; Escabasse, Virginie; Robard, L.; Roux, Adeline; Maurice, Jean; Sarlon, Gabrielle; Strunski, V.; Trévillot, V.; Vérillaud, Benjamin; Vironneau, P.

doi:10.1016/j.anorl.2016.09.010

Cited by 12 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Defining the best therapeutic option remains controversial. However, the best option should reduce epistaxis severity, improve quality of life, be repeated with the longest time interval, and be as minimally invasive as possible …”

Section: Discussionmentioning

confidence: 99%

“…We report the first series that combines SBI with CGS. The use of glue is rarely reported in the literature . When injected at the base of the telangiectasias, it induces an inflammatory reaction, acting similar to a sclerosing agent.…”

Section: Discussionmentioning

confidence: 99%

“…The use of sclerotherapy has also been described but only in retrospective studies. The optimal treatment is still debatable, but it should offer a long duration of action with few side effects …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia

Khoueir

Borsik²,

Camous³

et al. 2019

The Laryngoscope

View full text Add to dashboard Cite

Objectives/Hypothesis The objective of this study was to report for the first time on the results of submucosal injections of bevacizumab used in conjunction with cyanoacrylate glue sclerotherapy in hereditary hemorrhagic telangiectasia (HHT). Study Design Retrospective analytic chart review. Methods We performed a chart review that included all patients with HHT treated with intranasal bevacizumab and cyanoacrylate glue for refractory epistaxis at Lariboisiere University Hospital from 2013 with a minimum follow‐up of 6 months. We injected 100 mg (25 mg/mL) of bevacizumab diluted in 2 mL of serum at the base of the telangiectasias, and sclerotherapy with an injection of cyanoacrylate glue was used adjunctively. Treatment efficacy was based on changes in Epistaxis Severity Scores (ESS) and the Bergler‐Sadick Scale. Quality of life and patient satisfaction were evaluated using the Cantril Self‐Anchoring Ladder (CL) and Likert scale, respectively. Results Thirty‐one patients were included, with a mean follow‐up of 26.6 months. The average ESS score significantly decreased from 7.82 to 3.89 (P < .05). The Bergler‐Sadick score significantly improved (P < .05) following the treatment, including the frequency (from 2.74 to 1.64) and the quantity (from 2.54 to 1.51) scales. Quality of life was significantly improved (P < .05) using the CL score (from 4.16 to 7.22). The Likert satisfaction scale related to the treatment efficacy was high, with an average of 7.03 out of 10. No complications were noted. Conclusions Submucosal injections of bevacizumab in conjunction with cyanoacrylate glue sclerotherapy significantly reduced epistaxis and improved the quality of life in HHT. Prospective comparative studies are needed to further evaluate the significance of this treatment modality. Level of Evidence 3b Laryngoscope, 129:2210–2215, 2019

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia

Khoueir

Borsik²,

Camous³

et al. 2019

The Laryngoscope

View full text Add to dashboard Cite

show abstract

“…The therapeutic algorithm depends mainly on regional practices. Recent recommendations from the French ENT society show the poor level of evidence in many studies . One explanation is the variability of criteria selected to grade therapeutic efficacy and nasal bleeding severity.…”

Section: Discussionmentioning

confidence: 99%

“…Recent recommendations from the French ENT society show the poor level of evidence in many studies. 9 One explanation is the variability of criteria selected to grade therapeutic efficacy and nasal bleeding severity. The ESS was developed as a standardised method of assessing nasal bleeding severity in HHT.…”

Section: Comparisons With Other Studiesmentioning

confidence: 99%